Thursday 17 January, 2013
CANCER RESEARCH UK and its commercial arm Cancer Research Technology (CRT) are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The ‘master-switch’ experimental drug, owned by Astex Pharmaceuticals, could potentially treat a range of cancer types.
Cancer Research UK’s Drug Development Office (DDO) will fund, manage and sponsor this early-stage Phase I clinical trial of up to 40 patients at The Institute of Cancer Research, London, and The Royal Marsden Hospital.
The drug, AT13148, is one of eight drugs to be developed through Cancer Research UK’s Clinical Development Partnerships (CDP) programme, which is a joint initiative between the charity’s DDO and CRT. The programme develops promising cancer drugs that pharmaceutical companies do not have the resources to progress through early phase clinical trials to see if they can benefit cancer patients. Without this programme many promising drugs would be left on the shelves gathering dust.
AT13148 is a type of drug called a kinase inhibitor. Research in the laboratory has shown it can simultaneously block several different enzymes that control cell growth and cell death, and the drug killed a range of cancer cell types including sarcoma, breast and prostate. Many drugs block only a single enzyme and scientists hope that switching off cell signals at multiple points at the same time could increase the effectiveness of this drug.
Dr Udai Banerji, Cancer Research UK senior clinical lecturer at The Institute of Cancer Research and honorary consultant in medical oncology at The Royal Marsden, said: “There’s an urgent need to discover and develop new ways to beat cancers that do not respond to the treatments we have at the moment. By targeting cancer cells at a range of weak spots instead of just one, tumours will be less likely to develop resistance to this treatment. We’re very pleased that this multi-target drug has now reached patients in the clinical trial stage.
“It’s thanks to the generosity and time of patients that it’s possible to carry out clinical trials like this that could lead to new treatments for patients in the future.”
The novel agent came into the DDO requiring extensive preclinical development work.
Cancer Research UK scientists at the DDO and those funded at The Institute of Cancer Research demonstrated that the drug would be suitable for patients and, working together with specialist manufacturing organisations, developed a sophisticated method to make the drug in its most basic form. Finally, Cancer Research UK’s Formulation Unit at the University of Strathclyde manufactured the drug for the trial.
The molecule was originally discovered by scientists on the PKB drug discovery programme, a collaboration between Astex Pharmaceuticals, CRT and The Institute of Cancer Research, which ran from 2003 through to 2006.
Harren Jhoti, Astex Pharmaceuticals president and director, said: “We are very gratified with the progress that the collaboration has achieved and that this work has progressed into the clinic.”
Astex Pharmaceuticals can decide to develop the drug further based on the Phase I/IIa clinical trial data. If it chooses not to, Cancer Research Technology has the rights to secure an alternative partner and ensure the drug has every possible chance of reaching patients. The charity will receive a share of revenues generated by the drug to be channelled back into life-saving research.
Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office, said: “We’re delighted to open the first clinical trial of this experimental drug to find out if it can benefit cancer patients in the future.
“This molecule was brought to us at a very early stage in its development and, with the preclinical work now completed, we’re extremely pleased it’s obtained regulatory approval to enter the clinic.
“We’ve developed this molecule through our Clinical Development Partnerships initiative that has allowed us to form strong links with industry to take this promising drug forward. Without the programme it may have remained undeveloped and the clinical trial simply would not have been possible.”
For media enquiries please contact Emma Rigby on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.
Notes to editors
About Astex Pharmaceuticals
Astex Pharmaceuticals, Inc. is an international, NASDAQ-listed (ASTX) pharmaceutical company dedicated to the discovery and development of novel therapeutics with a focus on oncology. Astex Pharmaceuticals was formed out of a merger between SuperGen and Astex Therapeutics with locations in Dublin, CA and Cambridge, UK.
Astex Pharmaceuticals receives significant royalties on global sales of Dacogen® (decitabine) for Injection, a marketed drug developed by the company. Eisai and Janssen, the global marketers of Dacogen sell the product in over 35 countries.
Astex Pharmaceuticals has an advanced clinical portfolio with two prioritized programs in six phase II trials. Astex has partnered development programs and on-going collaborations with pharmaceutical companies including J&J, GSK, AZ and Novartis that could generate more than a billion dollars in milestone revenue as products and projects progress.
Astex is a recognized world leader in fragment-based drug discovery and uses its proprietary technologies to generate new drug candidates across multiple therapeutic indications. The fragment-based approach to drug discovery has been shown to be successful at identifying small molecules with optimal drug-like properties against difficult targets.
For more information about Astex Pharmaceuticals: http://www.astx.com.
The Institute of Cancer Research (ICR) is one of the world’s most influential cancer research institutes.
Scientists and clinicians at the ICR are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden Hospital and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR’s mission is to make the discoveries that defeat cancer. For more information visit www.icr.ac.uk
About The Institute of Cancer Research’s Cancer Research UK Cancer Therapeutics Unit
The Institute of Cancer Research’s Cancer Research UK Cancer Therapeutics Unit is the world’s leading academic drug discovery team. It has discovered 16 new drug candidates over the past six years, with six of these progressing to Phase I clinical trial and one drug – abiraterone – being licensed in the US, Canada and Europe for patients with advanced prostate cancer. This success was recently recognised by the American Association of Cancer Research’s Team Science Award.
About Cancer Research Technology
Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found at www.cancertechnology.com
About Cancer Research UK's Drug Development Office
Cancer Research UK’s Drug Development Office has an impressive record of developing novel treatments for cancer. It currently has a portfolio of around 35 new anti-cancer agents in preclinical development, phase I or early phase II clinical trials. Since 1982, the Cancer Research UK Drug Development Office has taken over 120 potential new anti-cancer agents into clinical trials in patients,six of which have subsequently made it to market and many others are still in clinical development. Marketed drugs include Temozolomide, a drug discovered by Cancer Research UK scientists, that is an effective new treatment for brain cancer and Abiraterone which was co-discovered by Cancer Research UK scientists to treat advanced prostate cancer. Six other drugs are in late development phase III trials. This rate of success is comparable to that of any pharmaceutical company.
About Cancer Research UK
- Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research
- The charity’s groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 3469 6699 or visit www.cancerresearchuk.org